HomeBUSINESS
BUSINESS

Gilead, JT Start Talks on Terminating Japan HIV Pacts
(Aug.27.2018)

Gilead Sciences and Japan Tobacco are launching discussions on the possible termination of their long-standing licensing deals for HIV agents in Japan as the big biotech now has a stand-alone commercialization plan for its new HIV triplet Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide fumarate (TAF)) in the country ...
(LOG IN FOR FULL STORY)

News Calendar